about
Differential behavioral effects of partial bilateral lesions of ventral tegmental area or substantia nigra pars compacta in ratsEpidemiology, environmental risk factors and genetics of Parkinson's disease.High-frequency stimulation of the entopeduncular nucleus improves dystonia in dtsz hamsters.Continuous high-frequency stimulation in freely moving rats: development of an implantable microstimulation system.Placebo-controlled chronic high-frequency stimulation of the subthalamic nucleus preserves dopaminergic nigral neurons in a rat model of progressive Parkinsonism.[Multiple system atrophy].Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group.Multiple system atrophy: current and future approaches to managementCoordinated reset neuromodulation for Parkinson's disease: proof-of-concept studyTime-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease.Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials.Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy.[(123)I]-IBVM SPECT imaging of cholinergic systems in multiple system atrophy: A specific alteration of the ponto-thalamic cholinergic pathways (Ch5-Ch6).A genome-wide association study in multiple system atrophy.L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.Analysis of the prion protein gene in multiple system atrophyTargeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerationsExosomes, an Unmasked Culprit in Neurodegenerative Diseases.Acquired hepatocerebral degeneration.Priorities in Parkinson's disease research.Movement disorders in 2013: diagnosing and treating PD-the earlier the better?Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategies.Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative.Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.Targeting α-synuclein: Therapeutic options.Which ante mortem clinical features predict progressive supranuclear palsy pathology?Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study.A cross-sectional study on drug use in multiple system atrophy.Multiple System Atrophy - State of the Art.Breathing variability and brainstem serotonergic loss in a genetic model of multiple system atrophy.Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy.Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease.Falls in ambulatory non-demented patients with Parkinson's disease.Age-related motor dysfunction and neuropathology in a transgenic mouse model of multiple system atrophy.The effects of electrode material, charge density and stimulation duration on the safety of high-frequency stimulation of the subthalamic nucleus in rats.Deep brain stimulation changes basal ganglia output nuclei firing pattern in the dystonic hamster.Dopamine depletion increases the power and coherence of beta-oscillations in the cerebral cortex and subthalamic nucleus of the awake rat.Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations.
P50
Q28278798-CFC47F8B-01AD-4B1D-921C-B38096A142AFQ30238483-9FB75CA7-EF45-4248-BDA4-93F2211C8C10Q33203722-4E08E8EC-AA74-4BCF-A84A-688A4E3AD0EAQ33302983-33D44C1A-F402-45A3-B07A-A708F486427BQ33307087-49CB6577-D282-4C7A-9FDA-A34C26687406Q33672654-B91AD130-AD0E-489A-9E84-80C024EA25FBQ34245237-7CBE8CF4-A61A-409A-BC6D-1C494DFE8C8CQ34409502-F0197B80-1EC8-4D1A-8ED3-D3582B59BA03Q34805547-E26250C1-8DAC-4263-B842-446C3220E6C6Q35622290-8D7E6378-BEFE-4787-8A31-47B8D8AEECF3Q35761616-031CAB3F-4545-451B-9B72-F8E7F6FDA24BQ37213903-1FC045A7-7979-4B9E-82BD-08C985559BC1Q37217139-D073C5CF-2A57-4338-89C4-7647F05F5D10Q37345458-5E29528F-4329-4989-A68F-AE132654D7D5Q37486030-DF6A6596-57FB-4797-A231-5EA0648E440FQ37503280-5BDBD25C-1CF3-4886-BF62-D75F0361F525Q37566684-79E9A7C3-2803-4D3E-937D-EA3152A94376Q37614565-F9B03F53-F091-448F-9054-A91E8FBCDEA7Q37865637-B55EE79A-D708-4B5F-90DE-01748C170107Q37870670-B6867CE5-2912-4751-A024-8A2F5CA050FCQ38176182-DA669B69-ABEE-4719-BFD3-5C834242D4E2Q38192319-7316E9B8-61A1-494B-81EF-D93EAD5FB7D9Q38204155-6EB161DA-CD03-4A8B-840A-96DE1B1626CBQ38486351-1558D9C6-EF41-48E8-9C89-9A256820BEF0Q38553874-64DB74FA-588F-46AA-8F36-6B2F6E0EC66FQ38754587-D34BF12F-453C-44CD-9D66-4B332F14C332Q38788274-3342584E-A5BF-4D2F-BF24-2D9FE21012B7Q38807324-E4C5FA84-0CEA-4250-A537-3A75D0964A0CQ39006423-19D20ABA-A4A1-4F83-978B-7DE58704F3F3Q39209254-79C7A100-6D2C-4DB5-B765-316AF3CB1630Q39220912-DF2F8749-9BA4-46CD-B8BD-F315EE3F0519Q39268815-73968FD1-7E94-4E3C-82E8-2584B3599990Q40181237-1A24BAFF-0E11-427A-BEBD-2D8DF59F842CQ40202363-487C0AC3-1652-4CA3-ADD1-8A2670AF63A9Q41111540-14BD0F67-F479-45B2-A703-0BD6A906EDD4Q42449176-26C2DBD7-8384-4B11-980F-E76623A931C1Q42466500-8A018073-F2D4-4B6A-AE50-C5A4E179E848Q42466970-C826A023-DF28-4B42-A936-80E3D0109917Q42476580-9A356C31-82D7-4F46-9428-AF0860BCC5ABQ42483167-8880DF84-18E2-430D-B541-AEB25FC75898
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Wassilios G. Meissner
@ast
Wassilios G. Meissner
@en
Wassilios G. Meissner
@es
Wassilios G. Meissner
@sl
type
label
Wassilios G. Meissner
@ast
Wassilios G. Meissner
@en
Wassilios G. Meissner
@es
Wassilios G. Meissner
@sl
altLabel
Wassilios G Meissner
@en
Wassilios Meissner
@en
prefLabel
Wassilios G. Meissner
@ast
Wassilios G. Meissner
@en
Wassilios G. Meissner
@es
Wassilios G. Meissner
@sl
P1053
C-7817-2015
P106
P1153
7102756596
P21
P2456
P31
P3829
P4012
P496
0000-0003-2172-7527